Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 11/20 | 0.61 |
| ▸ | IKZF3 | Q9UKT9 | 8/20 | 0.60 |
| ▸ | IKZF1 | Q13422 | 3/20 | 0.60 |
| ▸ | TNF | P01375 | 2/20 | 0.60 |
| ▸ | IL1B | P01584 | 2/20 | 0.60 |
| ▸ | BRD4 | O60885 | 1/20 | 0.60 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.60 |
| ▸ | IKZF2 | Q9UKS7 | 5/20 | 0.58 |
| ▸ | MAP1LC3B | Q9GZQ8 | 3/20 | 0.49 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26375232 | 0.90 | CRBN (0.49) | CRBNIKZF3IKZF1TNFIL1B | |
| SCHEMBL23105166 | 0.89 | CRBN (0.65) | CRBNIKZF3IKZF1TNFIL1B | |
| SCHEMBL22000908 | 0.88 | CRBN (0.73) | CRBNIKZF3IKZF1TNFIL1B | |
| SCHEMBL22000913 | 0.86 | CRBN (0.70) | CRBNIKZF3IKZF1TNFIL1B | |
| SCHEMBL24132344 | 0.86 | CRBN (0.61) | CRBNIKZF3IKZF1TNFIL1B | |
| SCHEMBL22000911 | 0.85 | CRBN (0.69) | CRBNIKZF3IKZF1TNFIL1B | |
| SCHEMBL24356134 | 0.84 | CRBN (0.57) | CRBNIKZF3IKZF1TNFIL1B | |
| SCHEMBL24356119 | 0.84 | IKZF2 (0.49) | CRBNIKZF3IKZF1TNFIL1B | |
| SCHEMBL19586849 | 0.84 | CRBN (0.67) | CRBNIKZF3IKZF1TNFIL1B | |
| SCHEMBL19586041 | 0.84 | CRBN (0.64) | CRBNIKZF3IKZF1TNFIL1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240025863-A1 | SOS1 PROTEIN DEGRADERS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND THEIR THERAPEUTIC APPLICATIONS | BIOTHERYX, INC. | 2024-01-25 | — | — | US | disclosed |
| US-20230293702-A1 | QUINAZOLINES, PHARMACEUTICAL COMPOSITIONS, AND THERAPEUTIC APPLICATIONS | BIOTHERYX, INC. | 2023-09-21 | — | — | US | disclosed |
| US-20230002371-A1 | RAS PROTEIN DEGRADERS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND THEIR THERAPEUTIC APPLICATIONS | BIOTHERYX INC (US) | 2023-01-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230293702-A1 | QUINAZOLINES, PHARMACEUTICAL COMPOSITIONS, AND THERAPEUTIC APPLICATIONS | RAB1A, SOS1, IQGAP1 | CRBN 3656/4885IKZF3 3769/4885IKZF1 3922/4885 |
| US-20230002371-A1 | RAS PROTEIN DEGRADERS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND THEIR THERAPEUTIC APPLICATIONS | KRAS, RSU1, RAB1A | CRBN 407/4885IKZF3 2315/4885IKZF1 2956/4885 |
| US-20240025863-A1 | SOS1 PROTEIN DEGRADERS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND THEIR THERAPEUTIC APPLICATIONS | SOS1, SOS2, SOST | CRBN 474/4885IKZF3 2458/4885IKZF1 1510/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.